{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T20:14:57Z","timestamp":1790540097909,"version":"4.1.0"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1097\/ico.0000000000000051","type":"journal-article","created":{"date-parts":[[2014,1,22]],"date-time":"2014-01-22T08:05:53Z","timestamp":1390377953000},"page":"257-260","source":"Crossref","is-referenced-by-count":56,"title":["Treatment of Ocular Rosacea With Once-Daily Low-Dose Doxycycline"],"prefix":"10.1097","volume":"33","author":[{"given":"Bianka","family":"Sobolewska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deshka","family":"Doycheva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Deuter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Pfeffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Schaller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfred","family":"Zierhut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-9-20210204","first-page":"996","article-title":". Rosacea in German.","volume":"7","author":"Gauwerky","year":"2009","journal-title":"J Dtsch Dermatol Ges"},{"key":"R2-9-20210204","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/j.1365-2133.1953.tb13185.x","article-title":"Rosacea with special reference to its ocular manifestations.","volume":"65","author":"Borrie","year":"1953","journal-title":"Br J Dermatol"},{"key":"R3-9-20210204","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/0039-6257(86)90034-2","article-title":"Ocular rosacea.","volume":"31","author":"Browning","year":"1986","journal-title":"Surv Ophthalmol"},{"key":"R4-9-20210204","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S0002-9394(43)91857-4","article-title":"Ocular rosacea.","volume":"26","author":"Wise","year":"1943","journal-title":"Am J Ophthalmol"},{"key":"R5-9-20210204","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/0002-9394(79)90525-7","article-title":". Ocular rosacea.","volume":"88","author":"Jenkins","year":"1979","journal-title":"Am J Ophthalmol"},{"key":"R6-9-20210204","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1016\/S0161-6420(97)30015-3","article-title":". Ocular rosacea: patient characteristics and follow-up.","volume":"104","author":"Akpek","year":"1997","journal-title":"Ophthalmology"},{"key":"R7-9-20210204","first-page":"721","article-title":"Rosacea and atopic dermatitis. Two common oculocutaneous disorders.","volume":"48","author":"Barankin","year":"2002","journal-title":"Can Fam Physician"},{"key":"R8-9-20210204","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/00003226-200304000-00009","article-title":". The prevalence of ocular signs in acne rosacea: comparing patients from ophthalmology and dermatology clinics.","volume":"22","author":"Ghanem","year":"2003","journal-title":"Cornea"},{"key":"R9-9-20210204","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1177\/112067210201200103","article-title":"Comparison of tear function tests and impression cytology with the ocular findings in acne rosacea.","volume":"12","author":"Yaylali","year":"2002","journal-title":"Eur J Ophthalmol"},{"key":"R10-9-20210204","first-page":"112","article-title":"The ocular manifestations of rosacea.","volume":"68","author":"Tanzi","year":"2001","journal-title":"Cutis"},{"key":"R12-9-20210204","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.jaad.2006.11.021","article-title":". Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea.","volume":"56","author":"Del Rosso","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"R13-9-20210204","first-page":"16","article-title":"Effectiveness and safety of doxycycline 40 mg (30-mg immediate-release and 10-mg delayed-release beads) once daily as add-on therapy to existing topical regimens for the treatment of papulopustular rosacea: results from a community-based trial.","volume":"86","author":"Del Rosso","year":"2010","journal-title":"Cutis"},{"key":"R14-9-20210204","first-page":"573","article-title":"Comparison of anti-inflammatory dose doxycycline versus doxycycline 100 mg in the treatment of rosacea.","volume":"7","author":"Del Rosso","year":"2008","journal-title":"J Drugs Dermatol"},{"key":"R15-9-20210204","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1159\/000235550","article-title":"Tetracycline actions relevant to rosacea treatment.","volume":"22","author":"Korting","year":"2009","journal-title":"Skin Pharmacol Physiol"},{"key":"R16-9-20210204","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1902\/jop.2007.070015","article-title":". Subantimicrobial dose doxycycline effects on osteopenic bone loss: microbiologic results.","volume":"78","author":"Walker","year":"2007","journal-title":"J Periodontol"},{"key":"R17-9-20210204","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.jaad.2004.01.048","article-title":". Standard grading system for rosacea: repost of the National Rosacea Society Expert Committee on the classification and staging of rosacea.","volume":"50","author":"Wilkin","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"R18-9-20210204","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1167\/iovs.10-6997f","article-title":". The international workshop on meibomian gland dysfunction: report of the diagnosis subcommittee.","volume":"52","author":"Tomlinson","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R19-9-20210204","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1097\/00003226-200310000-00008","article-title":"Grading of corneal and conjunctival staining in the context of other dry eye tests.","volume":"22","author":"Bron","year":"2003","journal-title":"Cornea"},{"key":"R20-9-20210204","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1167\/iovs.10-6997g","article-title":". The international workshop on meibomian gland dysfunction: report of the subcommittee on management and treatment of meibomian gland dysfunction.","volume":"52","author":"Geerling","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R21-9-20210204","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1902\/jop.2008.080051","article-title":". Doxycycline reduces lipopolysaccharide-induced inflammatory mediator secretion in macrophage and ex vivo human whole blood models.","volume":"79","author":"Cazalis","year":"2008","journal-title":"J Periodontol"},{"key":"R22-9-20210204","first-page":"443","article-title":"Inhibition of mitogen-induced human lymphocyte proliferative responses by tetracycline analogues.","volume":"35","author":"Thong","year":"1979","journal-title":"Clin Exp Immunol"},{"key":"R23-9-20210204","doi-asserted-by":"crossref","first-page":"14014","DOI":"10.1073\/pnas.93.24.14014","article-title":". A novel mechanism of action of tetracyclines: effects on nitric oxide synthases.","volume":"93","author":"Amin","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R24-9-20210204","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/s00417-005-0212-3","article-title":". Tear fluid levels of MMP-8 are elevated in ocular rosaceatreatment effect of oral doxycycline.","volume":"244","author":"Maata","year":"2006","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R25-9-20210204","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1167\/iovs.04-0929","article-title":". Doxycycline inhibits TGF-beta1-induced MMP-9 via Smad and MAPK pathways in human corneal epithelial cells.","volume":"46","author":"Kim","year":"2005","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R26-9-20210204","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/sj.bjp.0706823","article-title":". Matrix metalloproteinases contribute to endotoxin and interleukin-1beta induced vascular dysfunction.","volume":"149","author":"Lalu","year":"2006","journal-title":"Br J Pharmacol"},{"key":"R27-9-20210204","first-page":"904","article-title":". Treatment of ocular rosacea with 40 mg doxycycline in a slow release form.","volume":"9","author":"Pfeffer","year":"2011","journal-title":"J Dtsch Dermatol Ges"},{"key":"R28-9-20210204","doi-asserted-by":"crossref","first-page":"352","DOI":"10.3109\/09273948.2010.498657","article-title":"Clinical review: topical ophthalmic use of cyclosporin A.","volume":"18","author":"Utine","year":"2010","journal-title":"Ocul Immunol Inflamm"},{"key":"R29-9-20210204","first-page":"129","article-title":". Safety and efficacy of doxycycline in the treatment of rosacea.","volume":"2","author":"Valentin","year":"2009","journal-title":"Clin Cosmet Investig Dermatol"}],"container-title":["Cornea"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/ICO.0000000000000051","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T21:08:15Z","timestamp":1620940095000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00003226-201403000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/ico.0000000000000051","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718249213.793495898","asserted-by":"object"}]},"ISSN":["0277-3740"],"issn-type":[{"value":"0277-3740","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]}}}